{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:46:34Z","timestamp":1790934394307,"version":"4.1.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.clbc.2011.08.002","type":"journal-article","created":{"date-parts":[[2011,10,19]],"date-time":"2011-10-19T20:49:17Z","timestamp":1319057357000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor\u2013Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial"],"prefix":"10.1016","volume":"12","author":[{"given":"Antonio","family":"Llombart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Frassoldati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Outi","family":"Paija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harm Peter","family":"Sleeboom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Jerusalem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Mebis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Deleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Neven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2011.08.002_bib1","doi-asserted-by":"crossref","first-page":"122","DOI":"10.6004\/jnccn.2009.0012","article-title":"Breast cancer","volume":"7","author":"Carlson","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2011.08.002_bib2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2006.09.003","article-title":"Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations","volume":"43","author":"Thuerlimann","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2011.08.002_bib3","doi-asserted-by":"crossref","first-page":"971","DOI":"10.6004\/jnccn.2006.0082","article-title":"Adjuvant endocrine therapy in hormone receptor\u2013positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations","volume":"4","author":"Carlson","year":"2006","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clbc.2011.08.002_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.critrevonc.2008.07.013","article-title":"Aromatase inhibitor\u2013associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis","volume":"69","author":"Hadji","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 5","key":"10.1016\/j.clbc.2011.08.002_bib5","doi-asserted-by":"crossref","first-page":"v9","DOI":"10.1093\/annonc\/mdq159","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Aebi","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2011.08.002_bib7","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2011.08.002_bib8","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1056\/NEJMoa0810818","article-title":"Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer","volume":"361","author":"Mouridsen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2011.08.002_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib10","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor\u2013positive breast cancer","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/GCO.0b013e32831da80e","article-title":"Aromatase inhibitors and bone health","volume":"21","author":"Bundred","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.clbc.2011.08.002_bib12","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment\u2013induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","article-title":"Bone mineral density thresholds for pharmacological intervention to prevent fractures","volume":"164","author":"Siris","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clbc.2011.08.002_bib14","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/JBMR.040508","article-title":"Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA)","volume":"19","author":"Siris","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2011.08.002_bib15","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","article-title":"Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures","volume":"312","author":"Marshall","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.clbc.2011.08.002_bib16","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib18","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/cncr.23259","article-title":"Effective inhibition of aromatase inhibitor\u2013associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results","volume":"112","author":"Bundred","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clbc.2011.08.002_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2011.08.002_bib20","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib21","series-title":"Zometa\u00ae (zoledronic acid) injection","year":"2011"},{"key":"10.1016\/j.clbc.2011.08.002_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clbc.2011.08.002_bib26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1634\/theoncologist.2007-0152","article-title":"Cancer treatment-induced bone loss: pathophysiology and clinical perspectives","volume":"13","author":"Brufsky","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.clbc.2011.08.002_bib27","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib28","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2001.19.14.3306","article-title":"Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer","volume":"19","author":"Shapiro","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib29","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/annonc\/mdn164","article-title":"Practical guidance for the management of aromatase inhibitor-associated bone loss","volume":"19","author":"Hadji","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0140-6736(07)60200-1","article-title":"Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial","volume":"369","author":"Coombes","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.clbc.2011.08.002_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clbc.2011.08.002_bib32","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/jnci\/dji250","article-title":"Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17","volume":"97","author":"Goss","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"10.1016\/j.clbc.2011.08.002_bib33","first-page":"S113","article-title":"The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis","volume":"22","author":"Eastell","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.clbc.2011.08.002_bib34","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-07-5101","article-title":"Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer","volume":"14","author":"Lester","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clbc.2011.08.002_bib35","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2011.08.002_bib37","doi-asserted-by":"crossref","unstructured":"Brufsky A, Harker G, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Poster presented at 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, Texas; 2009: abstract 4083.","DOI":"10.1158\/0008-5472.SABCS-09-4083"},{"key":"10.1016\/j.clbc.2011.08.002_bib38","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/sj.bjc.6605604","article-title":"The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer","volume":"102","author":"Coleman","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2011.08.002_bib39","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy","author":"Coleman","year":"2011","journal-title":"N Engl J Med"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911001595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911001595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:05:02Z","timestamp":1761512702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911001595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1526820911001595"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2011.08.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor\u2013Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST Trial","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2011.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}